Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001044265 | SCV001208054 | uncertain significance | not provided | 2022-06-27 | criteria provided, single submitter | clinical testing | This sequence change replaces leucine, which is neutral and non-polar, with valine, which is neutral and non-polar, at codon 180 of the GNPTG protein (p.Leu180Val). This variant is present in population databases (rs776105074, gnomAD 0.02%). This variant has not been reported in the literature in individuals affected with GNPTG-related conditions. ClinVar contains an entry for this variant (Variation ID: 841944). Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Probably Damaging"; Align-GVGD: "Class C0"). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Ambry Genetics | RCV004973277 | SCV005595513 | uncertain significance | Inborn genetic diseases | 2024-09-10 | criteria provided, single submitter | clinical testing | The c.538C>G (p.L180V) alteration is located in exon 8 (coding exon 8) of the GNPTG gene. This alteration results from a C to G substitution at nucleotide position 538, causing the leucine (L) at amino acid position 180 to be replaced by a valine (V). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Natera, |
RCV001827271 | SCV002093809 | uncertain significance | GNPTG-mucolipidosis | 2021-06-25 | no assertion criteria provided | clinical testing |